Background: Gastric cancer is one of the main important causes of cancer death in Chile.

Objective: To report the results of adjuvant radiochemotherapy in advanced gastric cancer.

Material and Methods: Between 2000 and 2018, 214 subjects aged 23–85 (median, 62) years with lymph node and/or serosa involvement were treated with adjuvant chemoradiotherapy after curative resection.

Results: With a median follow-up of 41 months, overall 3- and 5-year survival was 54.9% and 40.85%, respectively. On multivariate analysis, the factors associated with lower survival were aged >65 years, stage group and number of lymph nodes involved.

Conclusion: In patients with locoregionally advanced gastric cancer treated with curative intent with surgery and adjuvant radiochemotherapy, the overall 5-year survival reported from local clinical practice is similar to that reported in randomised series and supports its use as an effective treatment for this type of patients in our country.